Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Retained Earnings: 2014-2024

Historic Retained Earnings for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Dec 2024 value amounting to -$995.9 million.

  • Viridian Therapeutics, Inc.\DE's Retained Earnings fell 32.96% to -$1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 billion, marking a year-over-year decrease of 32.96%. This contributed to the annual value of -$995.9 million for FY2024, which is 37.19% down from last year.
  • Viridian Therapeutics, Inc.\DE's Retained Earnings amounted to -$995.9 million in FY2024, which was down 37.19% from -$725.9 million recorded in FY2023.
  • Viridian Therapeutics, Inc.\DE's 5-year Retained Earnings high stood at -$278.9 million for FY2020, and its period low was -$995.9 million during FY2024.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Retained Earnings averaged around -$736.6 million, with its median value being -$725.9 million (2023).
  • Data for Viridian Therapeutics, Inc.\DE's Retained Earnings shows a maximum YoY slumped of 65.84% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Retained Earnings stood at -$278.9 million in 2020, then dropped by 28.47% to -$358.3 million in 2021, then tumbled by 36.25% to -$488.2 million in 2022, then slumped by 48.70% to -$725.9 million in 2023, then plummeted by 37.19% to -$995.9 million in 2024.